Jamie Rubin

The six-month saga of Pfizer's (NYSE: PFE) negotiations with AstraZeneca (NYSE: AZN) came to a crashing halt Monday with the rejection of Pfizer's $117 billion offer. Some analysts are now suggesting a break-up could be in the cards for the U.S. pharmaceuticals giant. Pfizer's "size is its...